Sitravatinib Enrolling by Invitation Phase 3 Trials for Advanced Malignant Neoplasm Treatment

IndicationsStatusPurposePhase
Enrolling by InvitationTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04164199Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies